The latest price target for Tandem Diabetes Care (NASDAQ:TNDM) was reported by Wells Fargo on June 1, 2026. The analyst firm set a price target for $27.00 expecting TNDM to rise to within 12 months (a possible 87.76% upside). 45 analyst firms have reported ratings in the last year.

The latest analyst rating for Tandem Diabetes Care (NASDAQ:TNDM) was provided by Wells Fargo, and Tandem Diabetes Care upgraded their overweight rating.

The last upgrade for Tandem Diabetes Care Inc happened on June 1, 2026 when Wells Fargo raised their price target to $27. Wells Fargo previously had an equal-weight for Tandem Diabetes Care Inc.

The last downgrade for Tandem Diabetes Care Inc happened on August 11, 2025 when Lake Street changed their price target from $75 to $12 for Tandem Diabetes Care Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tandem Diabetes Care, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tandem Diabetes Care was filed on June 1, 2026 so you should expect the next rating to be made available sometime around June 1, 2027.

While ratings are subjective and will change, the latest Tandem Diabetes Care (TNDM) rating was a upgraded with a price target of $21.00 to $27.00. The current price Tandem Diabetes Care (TNDM) is trading at is $14.38, which is out of the analyst’s predicted range.